Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Powell, Graham ^a   Saunders, Matthew ^b   Marson, Anthony G ^b  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE;

CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED RELEASE FORMULATION; DISEASE CONTROL; DISEASE DURATION; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPSY; HUMAN; IMMEDIATE RELEASE FORMULATION; INCIDENCE; MONOTHERAPY; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 85041721344     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007124.pub3     Document Type: Review

References (31)

1. Aldenkamp AP, Alpherts WC, Moerland MC, Ottevanger N, Van Parys JA. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987;28(5):507-14.
2. The Tegretol OROS Osmotic Release Delivery System Study Group. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Epilepsia 1995;45(9):1703-7.
3. Canger R, Altamura AC, Belvedere O, Monaco F, Monza GC, Muscas GC, et al.Conventional vs controlled release carbamazepine: a multicentre, double blind, crossover study. Acta Neurologica Scandinavica 1990;82(1):9-13.
4. Garnett WR, Levy B, McLean AM, Zhang Y, Couch RA, Rudnic EM, et al.Pharmacokinetic evaluation of twice daily extended release carbamazepine and four times daily immediate release carbamazepine in patients with epilepsy. Epilepsia 1998;39(3):274-9.
5. Kaski M, Heinonen E, Sivenius J, Tuominen J, Anttila M. Treatment of epilepsy in mentally retarded patients with a slow release carbamazepine preparation. Journal of Mental Deficiency Research 1991;35(pt 3):231-9.
6. McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Monotherapy with conventional and controlled release carbamazepine: a double blind, double dummy comparison in epileptic patients. British Journal of Clinical Pharmacology 1991;32(1):99-104.
7. Nag D, Garg RK, Agarwal A. A comparative evaluation of pharmacokinetics of conventional and slow release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation. Journal of the Association of Physicians of India 1998;46(2):185-8.
8. Persson LI, Ben, Menachem E, Bengtsson E, Heinonen E. Differences in side effects between a conventional carbamazepine preparation and a slow release preparation of carbamazepine. Epilepsy Research 1990;6(2):134-40.
9. Reunanen M, Heinonen E, Antila M, Jarvensivu P, Lehto H, Hokkanen E. Multiple dose pharmacokinetic study with a slow release carbamazepine preparation. Epilepsy Research 1990;6(2):126-33.
10. Sivenius J, Heinonen E, Lehto H, Jarvensivu P, Anttila M, Ylinen A, et al.Reduction of dosing frequency of carbamazepine with a slow release preparation. Epilepsy Research 1988;2(1):32-6.
11. Bojinova V, Belopitova L, Yotova R, Dimova P, Bojilova R, Tomov V. Carbamazepine -efficacy and applicability of its different preparations in therapy of the epilepsies of childhood. Epilepsia 1997;38 Suppl 3:96-7.
12. Dam M, Christiansen J, Kristensen CB, Helles A, Jaegerskou A, Schmiegelow M. Carbamazepine [Karbamazepin]. Ugeskrift for Laeger 1980;142:1504-7.
13. Dam M, Christiansen J, Kristensen CB, Helles A, Jaegerskou A, Schmiegelow M. Carbamazepine: a clinical biopharmaceutical study. European Journal of Clinical Pharmacology 1981;20(1):59-64.
14. Ghose K, Fry DE, Christfides JA. Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients. European Journal of Clinical Pharmacology 1983;24(3):375-81.
15. Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow release formulations. Acta Neurologica Scandinavica 1990;82(2):135-7.
16. Mirza WU, Rak IW, Thadani VM, Cereghino JJ, Garnett WR, Brown LM, et al.Six-month evaluation of Carbatrol (extended release carbamazepine) in complex partial seizures. Neurology 1998;19:1727-9.
17. Monaco F, Porcella V. A comparison of the bioavailability of two carbamazepine preparations (200mg and 400mg tablets). Journal of International Medical Research 1984;12(2):108-13.
18. Pieters MSM, Jennekens-Schinkel A, Stijnen T, Edelbroek PM, Brouwer OF, Liauw L, et al.Carbamazepine controlled release compared with conventional carbamazepine: A controlled study of attention and vigilance in children with epilepsy. Epilepsia 1992;33(6):1137-44.
19. Ramsay RE, Guterman A, McManus D, McJilton, Faleck H, Strollo A, et al.Comparative pharmacokinetics of Tegretol controlled release system to Tegretol in epileptic patients. Epilepsia 1989;30(5):638.
20. Remy C. Comparative open trial of carbamazepine and slow release carbamazepine in epilepsy in adults. [Etude ouverte comparative de la carbamazepine et de la carbamazepine a liberation prolongee dans l'epilepsie de l'adulte]. Presse Medicale 1990;19(11):511-3.
21. Scheuch E, Hoffman C, Franke G, Rabending G, Zschiesche M, Siegmund W. A bioequivalence study on retarded formulations of carbamazepine tablets. International Journal of Clinical Pharmacology, Therapy and Toxicology 1992;30(11):486-7.
22. Sobaniec W, Kulak W, Smigielska-Kuzia J, Bockowski L, Majkowski J, Jedrzejczak J. A multicentre, placebo controlled, double blind study of efficacy of a new form of carbamazepine (Carbatrol(R)) in refractory epileptic patients. Polish Journal of Pharmacology 2004;56(2):195-201.
23. Thakker KM, Mangat S, Faleck H, Cook T, Garnett W, Pellock J, et al.Steady-state bioavailability and fluctuations of carbamazepine following crossover administration of qid conventional Tegretol tablets and bid Tegretol OROS tablets. Epilepsia 1991;32 Suppl 3:3.
24. Collins RJ, Garnett WR. Extended release formulations of anticonvulsant medications, clinical pharmacokinetics and therapeutic advantages. CNS Drugs 2000;14(3):203-12.
25. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935 -1984. Epilepsia 1993;34(3):453-68. [PUBMED: 8504780]
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. The Cochrane Collaboration, UK.
27. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org/.
28. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW, on behalf of the epilepsy monotherapy trialists. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030]
29. NICE. The Epilepsies: Clinical Practice Guideline. http://www.nice.org.uk/nicemedia/pdf/CG020fullguideline_appendixB.pdf 2004.
30. Vojvodic NM, Sokic DV, Jankovic SM, Levic Z. A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy [Pragmaticna studija efikasnosti retard-preparata karbamazepina (Tegretol CR 400) u lecenju bolsenika s parcijalnim napadima epilepcije]. Srpski Arhiv za Celokupno Lekarstvo 2002;130(1-2):19-26.
31. Powell G, Saunders M, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007124.pub2]